N OWHERE HAVE THE POWER-and the limitations-of antimicrobial agents been more clearly revealed than in the control of rheumatic heart disease. On the one hand, we have an organism which in the test tube is exquisitely and uniformly sensitive to penicillin. And we can point with pride to the remarkable prophylactic record of antimicrobials in reducing the frequency of rheumatic recurrences. On the other hand, we must be cautious in attributing our currently favorable position exclusively or even primarily to the use of antimicrobials. A close examination of the statistics reveals that the rheumatic fever problem was declining before these agents were available. 1 The reasons for the beginning decline before the antibiotic era are obscure-possibly due to socioeconomic improvements such as changes in housing or even in nutrition. Since the reasons for this are obscure we must be guarded in our optimism that this trend will continue forever downward. Above all, we must not become mesmerized into believing that antibiotics are the final answer to the rheumatic fever problem, that all we have to do is improve our delivery of health care-spread enough penicillin widely and judiciously-and the disease will disappear completely and permanently.
We still have problems. Even with throat Pharyngitis Impetigo Rheumatic heart disease Nephritis cultures, we have problems in identifying and differentiating streptococcal infections.2' Despite uniform in vitro sensitivity, we still see and are puzzled by failures in eradicating streptococci from patients who have received "adequate" or repeated penicillin treatment. There is a continuing significant prevalence of streptococcal infections and their complications in the United States. In the many developing countries of this world and among the poor of our own country, rheumatic fever persists as a major cause of heart disease.1 4Lurking behind this is the possibility that the group A streptococcus may some day suddenly develop an in vitro resistance to penicillin.
For these reasons it is important that we not only intensify our efforts to apply existing knowledge but continue to devote a significant proportion of our energies and resources to understanding the pathogenesis of rheumatic heart disease and to developing alternative approaches to its control. Dr. T. Duckett Jones, whose contributions to this field we honor by this lecture series, put it this way: "The exact incidence of the disease, or the decrease in incidence or in severity, seems of less importance than the need to gain further knowledge of how and why human beings develop rheumatic fever . . . So long as surgeons find mitral stenosis requiring valvulotomy, or children and young adults continue to die of rheumatic fever and rheumatic heart disease, the problem exists. Rheumatic fever is and will remain with us until new knowledge and better preventive or therapeutic agents become available."5
Requirements for Development of Rheumatic Fever
For more years than most of us would like to admit, the basic skeleton of the sequence of events leading to the development of rheumatic heart 9 disease has been clear. Although intensive research has impressively expanded our knowledge of the biology of the group A streptococcus,6 and in recent years has revealed a bewildering and fascinating plethora of cross-reactions between streptococcal antigens and various mammalian tissues,7 we still have difficulties in fitting all of the pieces together in an all-embracing and workable concept of the pathogenesis of rheumatic heart disease.8
From a critical review of the evidence, one can single out a few absolute requirements for the development of acute rheumatic fever (table 1) 22 Lastly, the occurrence in some populations of repeated streptococcal infections of the skin due to a variety of types20' 22 should provide an excellent situation for the development of rheumatic fever and yet rheumatic fever does not occur. '2 Peculiarities of Streptococcal Impetigo Now let us examine some of the peculiarities of streptococcal impetigo and how these may relate to the failure of rheumatic fever to develop. First, in human volunteers it is possible to produce pharyngitis by simply placing group A streptococci in the nasopharynx.26 To produce cutaneous infections it is necessary to traumatize the skin and even with trauma one cannot produce these infections with consistency.'2' 27 Secondly, with streptococcal impetigo the initial lesion is vesicular.'2' 28 We never see vesicular lesions in streptococcal pharyngitis although we know that the mucous membranes of the oropharynx are able to react in this manner in response to certain viral agents.'2 Impetiginous lesions are essentially painless whereas pain is often a prominant feature in streptococcal pharyngitis. Of considerable interest-and with perhaps greater implications as to the pathogenesis of rheumatic fever-is the fact that the serotypes of streptococci associated with impetigo are different from those Circulation, Volume XLVIII, July 1973 commonly associated with infection of the upper respiratory tract.'12 22 The serotypes of streptococci associated with impetigo often have complicated and peculiar Tagglutination patterns, as originally pointed out by Parker and his coworkers29 in England. Most of these streptococci have been assigned high numbers in the M typing scheme since they have only recently been worked out. The numbers assigned to the most recently described new M types, most of which are associated with impetigo, can now be extended into the 60's.
The tendency for streptococcal impetigo to be more common in young children ' The initial studies from our own laboratory'8 in this area are summarized in fig. 1 connections between the pharyngeal tissues and the heart may be a direct route for living streptococci, L-forms, or streptococcal products to pass from one site to another. As figure 3 from the recent Russian literature shows,36 some impressive connections between the tonsils and the heart have been demonstrated by injection of lymphatic channels in cadavers. However, direct evidence that streptococci or their products actually travel this route is not available.
The differences in serologic types of group A streptococci which infect the skin and those which infect the throat12' 22, 37 may be a valuable lead which should be carefully scrutinized. However, studies to date have not revealed any consistent differences in these strains which seem to relate to the pathogenesis of rheumatic fever.
The existence of a definite carrier state in the throat-and its possible absence on the skin-may also be a significant factor since antibiotic treatment studies have associated persistence of the organism with development of rheumatic complications." Secretory factors may be important. Glynn and Holborow38 have postulated a role for salivary haptenes in the pathogenesis of rheumatic fever. While the significance of these findings is uncertain, for some time it has been known that the risk of developing rheumatic fever is related to the magnitude of the immunologic response. Although a similar relationship has been shown with several Arkh. Anat., 3 llar area with the heart. different streptococcal antigens, the most extensive data concern the antibody response to streptolysin 0. For both initial and recurrent attacks,44 45 the risk of developing rheumatic fever after group A streptococcal pharyngitis increases with an increase in the ASO response. Thus, in modifying the antigenic response to streptolysin 0, skin lipids may influence the risk of developing this complication.
We must also consider that skin lipids may have a more direct effect. In addition to its hemolytic properties, streptolysin 0 is toxic for a variety of figure 5 are shown intact actively pulsating heart cells. As shown in the panel on the right, within three minutes after exposure to streptolysin 0, these cells stop beating and develop blebs. All of these toxic manifestations of streptolysin 0 are inhibited by cholesterol.
Cholesterol as it is circulating in the blood is in a bound form and does not inhibit streptolysin 0. Even hypercholesteremic sera do not inhibit so that there may be something special about the state of cholesterol in the tissues which allows it to-be inhibitory.
In recent years cholesterol has received such a hostile reception in cardiology circles that it is probably heresy to suggest that in some situations it may have a salutary effect. Perhaps it is time that someone puts in a good word for cholesterol.
Journal of Experimental Figure 5 Changes in mammalian myocardial cells produced by streptolysin 0. la normal cells; lb = cells exposed to streptolysin 0.
In this regard it is of interest to recall the studies of Coburn47 of some years ago in which he thought that a factor in egg yolk was protective against rheumatic fever. It would be ironic indeed if our efforts to manipulate the diet, which are now being extended into the pediatric age group, would result in a population less susceptible to atherosclerosis but more susceptible to rheumatic fever.
Summary and Conclusions
To summarize, it is certain that cholesterol inhibits the hemolytic activity and the cardiotoxicity of streptolysin 0 and it is probable that it inhibits its antigenicity as well. Lipid extracts of skin containing cholesterol appear to inhibit both the hemolytic activity and the antigenicity of streptolysin 0. Whether they inhibit its cardiotoxicity is unknown but it would seem likely that they may.
With the overriding dominance of immunologic theories, it has not been fashionable in recent years to consider that rheumatic fever may develop from a direct toxic effect of a streptococcal product. Yet none of the antibodies described to date-crossreacting or otherwise-has been shown to have a cytotoxic effect on previously undamaged cells and for this as well as other reasons one cannot determine whether they are the cart or the horse. It is certainly possible that damage by a streptococcal toxin such as streptolysin 0 is necessary to initiate the rheumatic process, with cross-reacting antibodies or other factors contributing to its full development. And it is intriguing that this toxin may be inhibited when infection occurs at a particular site.
Obviously, the studies presented today are just a beginning, and much more work needs to be done to test the various hypotheses which have been mentioned.
One of the most serious handicaps to studies of the pathogenesis of rheumatic fever is the lack of a satisfactory laboratory model. With the notable exception of Claser et al.,48 few investigators have considered the site of infection in attempting to develop animal models, but it would seem important that experimental pathologists pay more attention to this aspect of the problem.
Another question which needs better documentation is whether other kinds of streptococcal skin infections such as erysipelas and infected burns, which may involve deeper tissues, and whether infection at other nonpharyngeal sites such as infection of the genitourinary tract, also fail to result in rheumatic fever. In Circulation, Volume XLVIII, July 1973 
